ValuEngine upgraded shares of Cellect Biotechnology Ltd. (NASDAQ:APOP) from a sell rating to a hold rating in a report issued on Tuesday, August 1st.
Separately, Rodman & Renshaw reissued a buy rating and set a $1.00 price objective (down previously from $10.00) on shares of Cellect Biotechnology in a research report on Tuesday, April 4th.
Cellect Biotechnology (NASDAQ APOP) traded up 7.29% during trading on Tuesday, hitting $7.06. 51,917 shares of the stock traded hands. The company’s 50 day moving average is $7.33 and its 200 day moving average is $7.63. Cellect Biotechnology has a one year low of $2.30 and a one year high of $13.50. The company’s market capitalization is $37.98 million.
About Cellect Biotechnology
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.